Bolanle Akinlade

5PUBLICATIONS
16CO-AUTHORS
AllergyInfant and child healthPharmacology and pharmaceutical sciences not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 15, 2026
Type-2-Inflammatory-Diseases Share Comorbidities, Molecular Signatures, IL4/IL13 Genetics, and Response to IL4/IL13 Blockade.

|Sep 24, 2020
Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study.

M J Cork, D Thaçi, L F Eichenfield

|Oct 10, 2019
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.

M J Cork, D Thaçi, L F Eichenfield

|May 09, 2019
Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis.

Lawrence F Eichenfield, Thomas Bieber, Lisa A Beck

|Mar 10, 2019
Conjunctivitis in dupilumab clinical trials.

B Akinlade, E Guttman-Yassky, M de Bruin-Weller

Pageof 1

Frequent Collaborators

2 joint publications

Marjolein de Bruin-Weller

2 joint publications

P D Arkwright

2 joint publications

A Bansal

1 joint publications

E Guttman-Yassky